Price Alert

Cardiff Oncology Inc. (CRDF)

NASDAQ: CRDF · Real-Time Price · USD

2.19

0.09 (4.29%)

At close: Oct 03, 2025, 3:59 PM

2.21

0.85%

After-hours: Oct 03, 2025, 07:24 PM EDT

4.29% (1D)

Bid	2.08
Market Cap	145.69M
Revenue (ttm)	546K
Net Income (ttm)	-51.02M
EPS (ttm)	-0.87
PE Ratio (ttm)	-2.52
Forward PE	-2.41
Analyst	Buy
Dividends	n/a

Ask	2.27
Volume	1,354,570
Avg. Volume (20D)	1,711,355
Open	2.12
Previous Close	2.10
Day's Range	2.10 - 2.21
52-Week Range	1.90 - 5.64
Beta	1.62
Ex-Dividend Date	n/a

About CRDF

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CRDF

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CRDF stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Cardiff Oncology Inc. is scheduled to release its earnings on Nov 6, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

9 months ago

+19.88%

Cardiff Oncology shares are trading higher after P... Unlock content with Pro Subscription

9 months ago

+54.92%

Cardiff Oncology shares are trading higher after the company announced the initial data from its CRDF-004 Phase 2 trial evaluating Onvansertib.

News

2 months ago · fool.com

Cardiff Oncology (CRDF) Q2 Loss Down 19%

2 months ago · benzinga.com

Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?

As advancements in cancer treatment continue to evolve, the pursuit of more effective therapies for metastatic colorectal cancer remains a critical focus in the pharmaceutical industry. Cardiff Oncolo...

2 months ago · seekingalpha.com

Cardiff Oncology: Data Update Resolves Some Signals

Onvansertib continues to show dose-dependent activity in KRAS-mutated mCRC, with response rates improving up to 49% in the high-dose arm. Recent data are less dramatic than early interim results, refl...

2 months ago · zacks.com

Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates

Cardiff Oncology (CRDF) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.26 per share a year ago.